- Home
- ACRS vs CAC Comparison
ACRS vs CAC Comparison
Compare ACRS & CAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACRS | CAC |
|---|---|---|
| Founded | 2012 | 1875 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 868.5M | 923.2M |
| IPO Year | 2015 | 1996 |
Fundamental Metrics
Financial Performance| Metric | ACRS | CAC |
|---|---|---|
| Price | $5.93 | $57.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | $10.20 | ★ $47.00 |
| AVG Volume (30 Days) | ★ 1.8M | 71.4K |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 3.51% |
| EPS Growth | ★ 69.01 | 6.08 |
| EPS | N/A | ★ 2.64 |
| Revenue | $1,683,000.00 | ★ $41,739,000.00 |
| Revenue This Year | N/A | $19.15 |
| Revenue Next Year | $4.24 | $6.05 |
| P/E Ratio | ★ N/A | $21.63 |
| Revenue Growth | N/A | ★ 16.96 |
| 52 Week Low | $1.74 | $35.00 |
| 52 Week High | $6.60 | $60.59 |
Technical Indicators
Market Signals| Indicator | ACRS | CAC |
|---|---|---|
| Relative Strength Index (RSI) | 50.42 | 55.65 |
| Support Level | $5.64 | $56.91 |
| Resistance Level | $6.56 | $60.07 |
| Average True Range (ATR) | 0.31 | 2.09 |
| MACD | -0.05 | -0.15 |
| Stochastic Oscillator | 33.34 | 67.79 |
Price Performance
Historical ComparisonAbout ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
About CAC Camden National Corporation
Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.